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Background
• Acute ischemic stroke (AIS) is an acute occlusion of an intracranial vessel reducing blood 
flow to region of the brain it supplies. AIS claims an estimated 200,000 deaths in the United 
States and is the leading cause of disability among adults.1
• The American Heart Association/American Stroke Association (AHA/ASA) recommends the 
delivery of thrombolytic therapy within 60 minutes of arrival to the emergency department. 
• To exclude hemorrhagic stroke, brain imaging is necessary in the process of thrombolytic 
delivery. Door-to-imaging (DIT) with computerized tomography (CT) or magnetic resonance 
imaging (MRI) are approved for AIS patients. Guidelines recommend DIT to occur within 25 
minutes of hospital arrival, highlighting the importance of a protocol for the emergency 
evaluation of patients with suspected stroke.
• The time from hospital arrival to brain imaging is thought to be a main driver of door-to-needle 
(DTN) time. While there is improvement in DITs, the DTN for intravenous administration 
varies widely in the United States and remain suboptimal.3
• Banner-University Medical Center – Tucson (BUMC-T) is an academic and comprehensive 
hospital located in Tucson, AZ. BUMC-T’s emergency department and it’s sister campus,  
Banner-University Medical Center – South Campus, has a combined census of 135,000 
patient visits per year.4
Importance
• Since early stroke treatment leads to better outcomes, door-to-needle time is recognized as 
an important quality indicator for the management of tPA.
• A head CT scan is required prior to tPA administration to exclude hemorrhagic stroke. At 
BUMC-T an MRI is conducted emergently to determine the need for neurological intervention 
in some circumstances. 
• The purpose of this quality improvement project was to determine the extent to which 
emergent MRI affects tPA administration in the emergency department (ED) at BUMC-T. 
Prior Research
• Yoo et al. (2010) compared MRI screening and MRI plus CT screening, showing patients with 
MRI had longer DTN times, but improved outcomes. 
• Lees et al. (2010) completed a meta analysis of ECASS, ATLANTIS, NINDS, and EPITHET 
trials showing reinforcing there is increase risk of hemorrhage and the net benefit was 
undetectable in their sample beyond 4.5 hours. 
• Fieback et al. (2002) evaluated the value of using MRI as a routine procedure compared to 
CT to exclude cerebral hemorrhage for tPA. Researchers concluded with the same delay after 
onset of AIS resulted in significant differences in diagnostic accuracy. MRI was substantially 
more sensitive and accurate compared to CT even with limited experience interpreters.
Objectives
Primary Objective: 
• To evaluate DTN times for the administration of tPA for patients who receive an emergent 
MRI for AIS. We hypothesized patients receiving an emergent MRI, will have a delay in 
treatment with tPA. 
Secondary Objective: 
• To determine if patients who receive an emergent MRI for AIS will have an interruption in tPA
treatment. We hypothesized patients receiving emergent MRI screenings will have an 
interruption during tPA infusion, prolonging tPA infusion times. 
• This was a retrospective cohort quality improvement project. Adult patients who received tPA at BUMC-T for AIS from January 2014 to January 2017 
were included. 
• A data collection form was created and used to extract information from patient charts. This included 3 items on demographics, 8 items on tPA use and 
dosing, 1 item on symptom onset, 1 item of ED admission, 5 items on utilization of CT, MRI, or interventional radiology (IR), 2 items on complication of 
tPA, and 2 items on scores of severity of stroke. 
• Data was collected from electronic medical records at BUMC-T and entered into a secured online data collection tool, REDCap. 
• The Wilcoxon Rank-Sum test was used to compare DTN times (in minutes of interquartile ranges) in patients who did or did not receive an emergent 
MRI. Descriptive data was analyzed using means and standard deviations. 
Data
Conclusion
References
• The reasoning for interruptions were documented and placed in the following categories:
1. MRI related
2. Blood pressure related
3. Adverse reactions related to tPA (eg, hematoma, headache, bleeding)
4. Other
• Most of the interruptions were due to ADE. Two patients were documented under “other” due 
to a change in reported symptom onset, disqualifying the patient from receiving tPA per 
BUMC-T’s protocol and a concern for sepsis with septic embolism and elevated risk of 
hemorrhage. 
• For the patients with an interruption in infusion, duration was 36 minutes at the 25th
percentile, 61 minutes at the 50th percentile, and 71 minutes at the 75th percentile. 
• Complications due to tPA were intracranial hemorrhage and death occurring in 15% and 9% 
of patients, respectively.
• Four of the 13 patients (31%) with a documented tPA interruption had an emergent MRI, and 
9 of 13 (61%) patients who did not have an emergent MRI, using Fisher’s exact test 
(P>0.05). This proportion was not statistically significant. 
• Patients utilizing MRI screening received tPA faster than patients who did not. This result 
was statistically significant using Wilcoxon Rank-Sum test. 
Table 1. Summary of patients with and without interruption in infusion and 
with and without emergent MRI
P-value: 0.073
Table 2. Summary of DTN times (minutes) in IQR ranges if patients did or 
did not receive an MRI
P-value: 0.0061
• A total of 96 patients were included in this project, with an average age 
of 67 years years and an average weight of 82 kg. Dosing on average 
was 72 mg. 
• Eight patients received a partial dose of tPA with 4 records of amount 
wasted. The recorded amount wasted ranged from 14 to 32 mg.
• The National Institutes of Health Stroke Scale (NIHSS) was evaluated 
in all but one patient prior to tPA administration. At the 50th percentile, 
these patient had a NIHSS of 9, and post administration NIHSS 
decreased to 2. This data however, was based on 86 patients, due to 
incomplete records due to death, transport to another hospital or other 
complication not related to tPA. 
• Time to symptom onset at the 50th percentile was 59 minutes and time 
to ED admit to CT screening was 10 minutes. 
• Median DTN was 62 minutes with a median infusion time of 61 minutes. 
• Nine percent of patients received an antihypertensive agent prior to 
infusion, these were labetalol or nicardipine. Seven percent of patients 
required an antihypertensive agent during infusion. 
• Fourteen percent of patients required an emergent MRI screening
• Twenty-two percent of patients received emergent IR.
• Thirteen patients had interruptions during tPA infusion. 
Variable (n=96) Mean SD
Age (years) 67 18
Weight (kg) 82 17
Alteplase dose given 72 13
Mean Percent (%)
Male 51 53
Female 45 47
Number Percent (%)
Patients with partial dose of alteplase (N=95) 8 8
Patients that received antihypertensive agent 
prior to alteplase infusion
9 9
Patients that received antihypertensive agent 
during alteplase infusion
7 7
Patients that received emergent interventional 
radiology
21 22
Number of patients with alteplase interrupted 13 14
Number of patients with reason for interruption, 
(N=13)
MRI related
Blood pressure related
ADE from alteplase
Other
4
1
6
2
30
8
47
15
Number of patients with complications due to 
alteplase
Intracranial hemorrhage
Death
14
9
15
9
Median IQR
NIHSS (prior to alteplase) 9 6-16
NIHSS (s/p alteplase) 2 0-6
Time from symptom onset to door 58 35-99
Time from door to computerized tomography 
(min)
10 4-16
Time from door to needle (min) 62 48-73
Duration of alteplase infusion (min) 61 60-63
Duration of alteplase infusion if interrupted (min) 61 36-71
Range
Amount of alteplase wasted (mg) 14-32
Results
No emergent MRI Emergent MRI Totals
No interruption 74 9 83
Interruption 13 4 13
Totals 83 13 96
N 25th percentile 50th percentile 75th percentile
No MRI 83 52 min 63 min 77 min
MRI 13 36 min 48 min 56 min
Total 96 48 min 62 min 73 min
Overall, emergent MRI did not delay the administration of tPA. MRI patients received tPA faster, 
which may be related to the characteristics of the patients. However, all preventable 
interruptions of tPA were related to emergent MRI (4 of 13 patients).
This quality improvement project suggests that a significant proportion of patients who require 
an emergent MRI may have errors during tPA administration and supports the need for 
pharmacists to follow the patient to MRI while being infused with thrombolytic therapy. 
Limitations:
• Data are from one site resulting in a small sample of participants. 
• Information collected was based on completeness and assumption of accuracy of the 
electronic health record 
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